AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03482817
Drug: Probe drug cocktail
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
Trial: NCT03745898
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nocturnal oxygen concentrator
Trial: NCT02807883
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
Trial: NCT01161004
Drug: Nacl 9/00 - sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
Trial: NCT01371708
Drug: DVS SR
RxNorm normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
Trial: NCT02097589
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
Trial: NCT02097589
Drug: Pneumovax 23
RxNorm normalized name: Pneumovax 23
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumovax 23 injected once, intramuscularly at Day 7.
Trial: NCT01830881
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Trial: NCT00002377
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002377
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02880943
Drug: XOFIGO
RxNorm normalized name: Xofigo
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg.
Trial: NCT01830881
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of 20 mL 1% lidocaine without epinephrine
Trial: NCT02614547
Drug: SAGE-547
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as intravenous infusion.
Trial: NCT02661191
Drug: oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and long-acting beta-agonists, salbutamol
Trial: NCT00736073
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Trial: NCT02397382
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.
Trial: NCT02397382
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
Trial: NCT02397382
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
Trial: NCT02397382
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
Trial: NCT02397382
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
Trial: NCT01495598
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg by mouth (p.o.) for 21 of 28 days
Trial: NCT01681615
Drug: Acetylsalicylate
RxNorm normalized name: Acetylsalicylate
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 drops
Trial: NCT01214993
Drug: Iohexol Injection
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol is an FDA approved radiologic contrast medium
Trial: NCT01214993
Drug: Para-aminohippurate infusion
RxNorm normalized name: para-aminohippurate
DrugBank: Aminohippuric acid (DB00345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.
Trial: NCT00490698
Drug: Zoledronate
RxNorm normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg IV Once Every 4 Weeks
Trial: NCT00490698
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg PO Daily
Trial: NCT00955890
Drug: Dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
Trial: NCT00955890
Drug: Dexrazoxane hydrochloride
RxNorm normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
Trial: NCT00994942
Drug: morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
Trial: NCT03600831
Drug: Docetaxel plus cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
Trial: NCT04126252
Drug: Sildenafil Citrate 50Mg Tab
RxNorm normalized name: SILDENAFIL CITRATE 50MG TAB
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
Trial: NCT00350727
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib is a novel compound being developed for the treatment of various cancers.
Trial: NCT00350727
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib is a novel compound being developed for the treatment of various cancers.
Trial: NCT00320229
Drug: abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03092817
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
Trial: NCT00788242
Drug: Glucose-insulin-potassium
RxNorm normalized name: glucose / potassium chloride
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Trial: NCT03889145
Drug: Telmisartan 80mg
RxNorm normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80mg
Trial: NCT03889145
Drug: Amlodipine10mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10mg
Trial: NCT03889145
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25mg
Trial: NCT01976572
Drug: colestilan
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01976572
Drug: candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413281
Drug: ALKS 5461
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets, single administration
Trial: NCT02413281
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual tablets, single administration
Trial: NCT04155203
Drug: Mupirocin Calcium
RxNorm normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mupirocin cream
Trial: NCT04155203
Drug: Mupirocin Calcium
RxNorm normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference mupirocin cream
Trial: NCT01755377
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02592876
Drug: denintuzumab mafodotin
RxNorm normalized name: Denintuzumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
Trial: NCT02592876
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
Trial: NCT02592876
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
Trial: NCT02592876
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
Trial: NCT02592876
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
Trial: NCT03551691
Drug: Omeprazole 20mg Capsule
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 20mg daily for 28 days
Trial: NCT03567629
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
Trial: NCT03567629
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
Trial: NCT00994175
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003072
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003072
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003072
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01306175
Drug: Digoxin plus BI 10773
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
Trial: NCT01306175
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin 0.5 mg as single dose
Trial: NCT02136498
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard 12 week course of varenicline, provided in both arms
Trial: NCT00368108
Drug: 2 mg perampanel
RxNorm normalized name: perampanel 2 MG
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg perampanel
Trial: NCT00319800
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00319800
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00368108
Drug: 4 mg perampanel
RxNorm normalized name: perampanel 4 MG
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg perampanel
Trial: NCT02737826
Drug: Buprenorphine Initiation - Phase I
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
Trial: NCT02737826
Drug: Gabapentin + Buprenorphine - Phase II
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Trial: NCT02737826
Drug: Placebo + Buprenorphine - Phase II
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
Trial: NCT02737826
Drug: Buprenorphine taper - Phase II
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
Trial: NCT02666664
Drug: ETC-1002
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Trial: NCT00551850
Drug: AV-412
RxNorm normalized name: AV-412
DrugBank: AV-412 (DB06021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
Trial: NCT00720564
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00720564
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01122875
Drug: MFGR1877S
RxNorm normalized name: MFGR1877S
DrugBank: Vofatamab (DB14781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT02432664
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Trial: NCT01425632
Drug: TAU-284
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU-284 Low
Trial: NCT01425632
Drug: TAU-284
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU-284 High
Trial: NCT01109511
Drug: naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01109511
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03364439
Drug: Treatment plan
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
Trial: NCT00919451
Drug: ciclosporin
RxNorm normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
Trial: NCT02539849
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00129935
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00129935
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02047162
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03514615
Drug: Active gel
RxNorm normalized name: Activated Charcoal
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The incision site on one arm will be dosed with the active gel.
Trial: NCT01145989
Drug: AT9283
RxNorm normalized name: AT9283
DrugBank: AT9283 (DB05169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
Trial: NCT02328118
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
Trial: NCT02328118
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
Trial: NCT00803192
Drug: Famotidine Tablets, 40 mg
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00214253
Drug: Thiazolidinedione
RxNorm normalized name: Thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
Trial: NCT03680339
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Trial: NCT03680339
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 IU of oxytocin with fetal delivery
Trial: NCT04115072
Drug: Praziquantel 600Mg Oral Tablet x 5
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five doses of Praziquantel 40 mg/kg
Trial: NCT04115072
Drug: Praziquantel 600Mg Oral Tablet x 1
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Praziquantel 40 mg/kg